Tag: bruton’s tyrosine kinase (BTK)

Long-term dual antiplatelet therapy does not increase mortality risk

Sanofi wins approval for first Bruton’s tyrosine kinase inhibitor in immune thrombocytopenia

byDeepti Shroff

September 9, 2025

1. The FDA approved rilzabrutinib, branded Wayrilz, as the first BTK (Bruton’s tyrosine kinase) inhibitor for adults with ITP (immune ...

#VisualAbstract Acalabrutinib monotherapy has acceptable tolerability and limited response in patients with Richter transformation

byKathleen Lau

November 11, 2021

#VisualAbstract Phase 2 trial shows umbralisib is safe and effective in patients with chronic lymphocytic leukemia who are intolerant to BTK or PI3Kδ inhibitor therapy

byKathleen Lau

June 4, 2021

Combined lenalidomide and rituximab dose escalation found to be safe for CLL

Pirtobrutinib is safe and efficacious in the treatment of relapsed or refractory B-cell malignancies (BRUIN Trial)

byMichael Pratteand1 others

March 18, 2021

1. Bruton’s tyrosine kinase inhibitor pirtobrutinib showed efficacy in the treatment of relapsed or refractory B-cell malignancies such as chronic ...

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result